Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346157 · ClinicalTrials.gov registry record · Phase 1
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT07346157: Clinical Trial Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
NCT07346157 is a Phase 1 study that has not yet begun recruiting, run by Sabine Mueller, MD, PhD. The registered enrollment target is 69 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07346157, a Phase 1 study, has not yet begun recruiting, sponsored by Sabine Mueller, MD, PhD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
Primary Outcome
Proportion of participants with adverse events of L-T3 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0)
Interventions
- DRUG Bevacizumab
- DRUG Irinotecan
- DRUG Temozolomide (TMZ)
- DRUG Liothyronine (L-T3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2026-07-30 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 1 |
What is known before NCT07346157 opens enrollment
NCT07346157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07346157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07346157 about?
NCT07346157 is a clinical study titled "Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease". This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
What is the current status of trial NCT07346157?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2026-07-30. Estimated completion is 2031-03-31.
What interventions are being tested in trial NCT07346157?
The interventions under investigation include: Bevacizumab (DRUG), Irinotecan (DRUG), Temozolomide (TMZ) (DRUG), Liothyronine (L-T3) (DRUG).
Who is sponsoring clinical trial NCT07346157?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07346157's enrollment target sits among peer trials
69 774th of 2000 higher than 1,225 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI